A Study of Closed Cases: Implications for the Administration of Deafness Rehabilitation Services

Non

What Does “Resistance” Actually Look Like? The Respecification of Resistance as an Interactional Accomplishment

In this introductory article to the special issue on Resistance in Talk-in-Interaction, we review the vast body of research that has respecified resistance by investigating it as and when it occurs in real-life encounters. Using methodological approaches such as ethnomethodology, conversation analysis, and discursive psychology, studies of resistance “in the wild” treat social interaction as a sequentially organized, joint enterprise. As a result, resistance emerges as the alternative to cooperation and therefore, on each occasion, resistant actions are designed to deal with the sequential and moral accountabilities that arise from the specifics of the situation. By documenting the wide array of linguistic, prosodic, sequential, and embodied resources that individuals use to resist the requirements set by interlocutors’ prior turns, this article provides the first comprehensive overview of existing research on resistance as an interactional accomplishment.</p

Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management?

Direct and indirect costs of nephrolithiasis in an employed population: Opportunity for disease management?BackgroundMore than 5% of the United States population has been diagnosed with nephrolithiasis and about one half of (first-time) stone formers will have a recurrence within 5 years. The prevalence of nephrolithiasis is concentrated among working age adults, yet little prior work has examined the economic burden of the disease on employers and their employees. We sought to estimate the direct and indirect costs of nephrolithiasis for working age adults (18-64) with employer-provided insurance.MethodsThis was an observational study using retrospective claims data. Detailed medical and pharmacy claims from 25 large employers and absentee data from a subset of firms were used to estimate the direct and indirect costs associated with nephrolithiasis in a privately insured, nonelderly population. Multivariate regression models were used to predict health care expenditures for persons with and without the condition, controlling for differences in patient (health status) and plan characteristics.ResultsMore than 1% of working-age adults were treated for nephrolithiasis in 2000. Prevalence was considerably higher among men and employees age 55 to 64. About one third of employees treated for nephrolithiasis in 2000 missed work due to the condition, with an average work loss for the entire treated population of 19 hours per person. Conditional on receiving treatment, the incremental costs of nephrolithiasis were $3,494 per person in 2000.ConclusionThe direct and indirect costs of nephrolithiaisis are substantial among working-age adults. Interventions that prevent recurrence among known stone formers may be a cost-effective component of disease management programs

Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk

Background Hyperlipidemia and hypertension are modifiable risk factors for Alzheimer's disease and related dementias (ADRD). Approximately 25% of adults over age 65 use both antihypertensives (AHTs) and statins for these conditions. While a growing body of evidence found statins and AHTs are independently associated with lower ADRD risk, no evidence exists on simultaneous use for different drug class combinations and ADRD risk. Our primary objective was to compare ADRD risk associated with concurrent use of different combinations of statins and antihypertensives. Methods In a retrospective cohort study (2007-2014), we analyzed 694,672 Medicare beneficiaries in the United States (2,017,786 person-years) who concurrently used both statins and AHTs. Using logistic regression adjusting for age, socioeconomic status and comorbidities, we quantified incident ADRD diagnosis associated with concurrent use of different statin molecules (atorvastatin, pravastatin, rosuvastatin, and simvastatin) and AHT drug classes (two renin-angiotensin system (RAS)-acting AHTs, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin-II receptor blockers (ARBs), vs non-RAS-acting AHTs). Findings Pravastatin or rosuvastatin combined with RAS-acting AHTs reduce risk of ADRD relative to any statin combined with non-RAS-acting AHTs: ACEI+pravastatin odds ratio (OR) = 0.942 (CI: 0.899-0.986, p = 0.011), ACEI+rosuvastatin OR = 0.841 (CI: 0.794-0.892, p< 0.001), ARB+pravastatin OR = 0.794 (CI: 0.748-0.843, p< 0.001), ARB+rosuvastatin OR = 0.818 (CI: 0.765-0.874, p< 0.001). ARBs combined with atorvastatin and simvastatin are associated with smaller reductions in risk, and ACEI with no risk reduction, compared to when combined with pravastatin or rosuvastatin. Among Hispanics, no combination of statins and RAS-acting AHTs reduces risk relative to combinations of statins and non-RAS-acting AHTs. Among blacks using ACEI+rosuvastatin, ADRD odds were 33% lower compared to blacks using other statins combined with non-RAS-acting AHTs (OR = 0.672 (CI: 0.5480.825, p<0.001)). Conclusion Among older Americans, use of pravastatin and rosuvastatin to treat hyperlipidemia is less common than use of simvastatin and atorvastatin, however, in combination with RAS-acting AHTs, particularly ARBs, they may be more effective at reducing risk of ADRD. The number of Americans with ADRD may be reduced with drug treatments for vascular health that also confer effects on ADRD.Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Understanding the emergence and evolution of new business models in the UK regenerative medicine sector

This paper identifies, characterises and analyses six evolving regenerative business (RM) models in the UK based on 10 cases we studied. Our conceptual framework extracts four key elements from contemporary business model and value chain literature; architecture/structure, value creation and extraction, networks and linkages, and governance. Using the case study method, we identified the following business models: materials and service provision; early exit: Phase I/II; manufacturing and scale up; translational services; virtual; and integrated. All the business models are still pre-revenue, except for manufacturing and scale up which generates revenue from contract manufacturing therapies for clinical trials. The RM sector is still evolving and consequently the business models are still in flux. Two key challenges for the sector are scalability and sustainability, which creates challenges for pre-emptive policy and practice interventions. We conclude that pre-emptive policy design should support value chain upgrading, paying particular attention to short, medium and long-term sustainability of the RM innovation eco-system, especially evolution of a broad base of SMEs that can take over when public funding is withdrawn. A proportionate and adaptive regulatory environment will be critical to supporting evolving business models even as value chain upgrading occurs

The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity

<div><p>Background</p><p>Antihypertensive treatments have been shown to reduce the risk of Alzheimer’s disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer differential and additional protective benefits against AD compared with other AHTs, in addition to hypertension management.</p><p>Methods</p><p>In a retrospective cohort design, we examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis for 1,343,334 users of six different AHT drug treatments, 65 years of age or older (4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted for age, socioeconomic status, underlying health, and comorbidities.</p><p>Findings</p><p>RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting AHTs for males, (male OR = 0.931 (CI: 0.895–0.969)), but not so for females (female OR = 0.985 (CI: 0.963–1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both men (male ARB OR = 0.834 (CI: 0.788–0.884); male ACEI OR = 0.978 (CI: 0.939–1.019)) and women (female ARB OR = 0.941 (CI: 0.913–0.969); female ACEI OR = 1.022 (CI: 0.997–1.048)), but only in white men and white and black women. No association was shown for Hispanic men and women.</p><p>Conclusion</p><p>Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.</p></div

HIV/AIDS/STI Surveillance Report:Report Number 21

Since the first cases of Acquired Immunodeficiency Syndrome (AIDS) in Tanzania were reported in 1983, the epidemic has evolved from being a rare and new disease to a common household problem, which has affected most Tanzania families. The mainland Tanzania faces a generalized human immunodeficiency virus (HIV) and AIDS epidemic, with an estimated 6.5% of the mainland population infected with HIV (7.7% of adult women and 6.3% of adult men). Overall, 1.4 million Tanzanians (1,300,000 adults and 110,000 children) are living with HIV infection, in a total population of 41 million. The social, economic, and environmental impact of the pandemic is sorely felt as an estimated 140,000 Tanzanians have perished, leaving behind as estimated 2.5 million orphans and vulnerable children, representing approximately 10-12% of all Tanzanian children. As elsewhere in sub-Saharan African, the underlying factors of poverty, migration, marginalization, lack of information and skills, disempowerment, and poor access to services raise the risk of HIV and have an impact on the course and spread of the pandemic. Close to 85% of HIV transmission in Tanzania occurs through heterosexual contact, less than 6% through mother-to-child transmission, and less than 1% through blood transfusion. There continues to be a significant difference in the prevalence among urban (10.9%) and rural (5.3%) areas of the country. The National AIDS Control Programme (NACP) of Tanzania was founded in 1987 to champion the health sector response to the HIV epidemic. The primary objectives of the program were to reduce spread of HIV infection, screen blood supplies, enhance clinical services for HIV/AIDS patients and improve STI treatment, prevention of mother-to-child transmission (PMTCT), advocate behavioral change and conduct epidemiologic surveillance and other research. The program phases started with a two-year phase called Short Term Plan\ud (1985-1986). Subsequent phases were termed Medium Term Plans lasting for five-year periods. Through these program phases successful national responses have been identified, the most effective ones being those touching on the major determinants of the epidemic and addressing priority areas that make people vulnerable to HIV infection. These include the following; Since early eighties great efforts have been made to reduce spread of HIV infection through screening of donor blood, advocating behavioral change, condom promotion and improvement of STI treatment. In addition a number of epidemiologic surveillance have been conducted to monitor the trend of HIV infection among different subpopulations e.g. blood donors and pregnant women attending antenatal clinics. In 2004, the National Blood Transfusions Services (NBTS), which is a centralized system of coordinated blood transfusion services, was established. The NBTS is responsible for collection, processing, storage and distribution of safe blood and blood products to health facilities. At the moment NBTS coordinates eight zonal blood transfusion centers, namely Lake Zone-(LZBTC) in Mwanza region, Western-(WZBTC) in Tabora, Northern (NZBTC) in Kilimanjaro region, Eastern (EZBTC) in Dar es Salaam, Southern highlands (SHZBTC) in Mbeya, Southern (SZBTC) in Mtwara and Zanzibar and a military zone –Tanzania People’s Defence Force (TPDF). Since the establishment of NBTS, donated blood in the eight zones is systematically screened for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis. The National HIV Care and Treatment Plan (NCTP) was launched in October 2004, with the main focus of a rapid scaling up of HIV care and treatment services, aimed at having more than 400,000 patients on care and treatment by the end of 2008 and, at the same time, follow up disease progression in 1.2 million HIV+ persons who are not eligible for ntiretroviral therapy (ART). Prevention of Mother to Child Transmission of HIV (PMTCT) services were established in 2002 , providing a package of services that include: counseling and testing for pregnant women; short-course preventive ARV regimens to prevent mother-to-child transmission; counseling and support for safe\ud infant feeding practices; family planning counseling or referral; and referral for long-term ART for the\ud child. This report which covers the NACP activities through December 2008 has been arranged in five chapters and is intended for various stakeholders, primarily those working within the health sector.\u